In renal carcinoma 786-O cells, elacridar used at higher concentrations (2.5 μM and 5 μM) in combination with sunitinib enhanced cytotoxicity by inhibiting P-gp activity [65]. This evidence concerns the gene PGP and renal carcinoma.